

ASX ANNOUNCEMENT

20 May 2026

Purchasing agreement secured with CHRISTUS Health

Key highlights:

- EBR has secured a three-year purchasing agreement with CHRISTUS Health
- CHRISTUS Health is the ninth-largest hospital network in the United States
- Agreement establishes a purchasing pathway for the WiSE® CRT System across a network of 66 hospitals
- Supports more efficient procurement and broader hospital access as EBR's U.S. commercial rollout continues

Sunnyvale, California; 20 May 2026: EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing device for heart failure, announces it has secured a purchasing agreement with CHRISTUS Health, marking a further step in the commercial rollout of its WiSE CRT System.

CHRISTUS Health is a Catholic, not-for-profit, mission-driven health system and the ninth-largest hospital network in the United States. The network comprises more than 600 centres, including 66 hospitals and employs more than 45,000 team members, including 15,000 clinicians. Its network is primarily located across Texas, Louisiana and New Mexico.

John McCutcheon, EBR Systems' President & Chief Executive Officer said:

"We are pleased to establish a purchasing agreement with CHRISTUS Health, an organization recognized for its commitment to patient-centered care. This agreement helps broaden institutional access to the WiSE CRT System and supports our ongoing efforts to bring leadless CRT therapy to more patients across the U.S."

EBR sales reps can now engage directly with individual CHRISTUS Health physicians at suitable locations to bring WiSE to their patients. Over time, the arrangement is expected to support broader hospital access across a large faith-based, mission-driven care network as the U.S. rollout continues.

For more information about EBR, please visit <https://www.ebrsystemsinc.com/>.

ENDS

This announcement has been authorised for release by the EBR Systems Routine Disclosure Committee, a Committee of the Board of Directors.

For more information, please contact:

Company

Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrwise.com

Investor Relations

Gabriella Hold
The Capital Network
P: +61 2 8999 3699
E: gaby@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR SYSTEMS, INC. (ARBN 654 147 127)

480 Oakmead Parkway, Sunnyvale CA 94085 USA T: +1 408 720 1906 W: <https://ebrsystemsinc.com/>

DM_HC 3005029-1.125021.0612

For personal use only

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

About CHRISTUS Health

CHRISTUS Health is a Catholic, not-for-profit, mission-driven health system made up of more than 600 centres, including hospitals, clinics and long-term care facilities. CHRISTUS Health says its network is primarily located in Texas, Louisiana, New Mexico, Chile, Colombia and Mexico.

For more information about CHRISTUS Health, please visit: <https://www.christushealth.org/>